Literature DB >> 6648806

Adrenal cortical carcinoma--a continuing challenge.

D J Henley, J A van Heerden, C S Grant, J A Carney, P C Carpenter.   

Abstract

The records of 62 patients (36 female and 26 male) with pathologically confirmed adrenal cortical carcinoma who had operations between 1960 and 1980 were reviewed. The mean age was 48 years. There were 36 (58%) functioning tumors and 26 (42%) nonfunctioning tumors. Curative resection was performed in 31 patients, palliative resection in 14, and open biopsy alone in 17 with an overall operative mortality rate of 9.7% and a 5-year survival rate of 16%. There was no significant difference in survival rates between patients who had operations alone and those who had operations plus adjunctive therapy. Patients with stages I to III lesions or those who underwent curative resections had significantly longer survival than had those with stage IV disease or those who had palliative resections, respectively. Factors that failed to influence survival rates included palliative resection versus biopsy, tumor size, grade, function, and patient sex or age. We conclude that operative staging is prognostically valuable, aggressive surgical treatment is recommended in stages I to III lesions, and a prospective randomized study of adjuvant treatment for all stages of adrenal cortical carcinoma is indicated.

Entities:  

Mesh:

Year:  1983        PMID: 6648806

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  22 in total

Review 1.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 2.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

3.  Andrenocortical carcinomas: twelve-year prospective experience.

Authors:  Libuse Tauchmanovà; Annamaria Colao; Luigi Antonio Marzano; Lucianna Sparano; Luigi Camera; Annalisa Rossi; Giovanna Palmieri; Ettore Marzano; Marco Salvatore; Guido Pettinato; Gaetano Lombardi; Riccardo Rossi
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

Review 4.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

6.  Results of adrenal surgery for Cushing's syndrome: 10 years' experience.

Authors:  R G Watson; J A van Heerden; R C Northcutt; C S Grant; D M Ilstrup
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

7.  A feminizing adrenocortical carcinoma presenting with gynaecomastia.

Authors:  D Lanigan; R G Choa; J Evans
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

Review 8.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 9.  Nonfunctional adrenal cortical carcinoma. Report of a case and review of the literature.

Authors:  E D Fokaefs; M D Melekos; M P Melachrinou; I E Zarakovitis; G A Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

10.  Nonfunctioning adrenocortical carcinoma in a young girl.

Authors:  H Kishikawa; T Mizuno; I Takagi; Y Yamakawa; T Shimozato; K Honda; M Tatematsu
Journal:  Jpn J Surg       Date:  1985-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.